Prosight Management, LP Pliant Therapeutics, Inc. Transaction History
Prosight Management, LP
- $378 Million
- Q3 2025
A detailed history of Prosight Management, LP transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Prosight Management, LP holds 20,487 shares of PLRX stock, worth $35,442. This represents 0.01% of its overall portfolio holdings.
Number of Shares
20,487
Previous 837,400
97.55%
Holding current value
$35,442
Previous $971,000
96.91%
% of portfolio
0.01%
Previous 0.26%
Shares
3 transactions
Others Institutions Holding PLRX
# of Institutions
112Shares Held
58.9MCall Options Held
209KPut Options Held
102K-
Tang Capital Management LLC San Diego, CA6MShares$10.4 Million0.4% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$8.6 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA4.5MShares$7.79 Million0.03% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct4.34MShares$7.51 Million0.01% of portfolio
-
Morgan Stanley New York, NY3.51MShares$6.07 Million0.0% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $84.2M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...